GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alumis Inc.
The shares of Alumis, a biotech focused on treating immune diseases, reflect the potential of its scientific platform. The post-IPO price will depend on the progress of its clinical trials and investor confidence in this new therapeutic approach.
Share prices of companies in the market segment - Pharma neurology
Alumis is a biopharmaceutical company developing oral medications for the treatment of immune-mediated diseases using a precision medicine approach. We classify it in the Pharmaceuticals (Neurology) sector. The chart below illustrates the dynamics of this innovative segment.
Broad Market Index - GURU.Markets
Alumis is a biopharmaceutical company developing targeted therapies for autoimmune diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Alumis shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ALMS - Daily change in the company's share price Alumis Inc.
The volatility of Alumis, a biopharmaceutical company focused on immunology, reflects the high risks of the biotech sector. Change_co is an immediate reaction to clinical trial news. This metric is the basis for analysis of the autoimmune drug development sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Alumis Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ALMS's performance, which is dependent on clinical trial results, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Alumis is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess the performance of Alumis shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alumis Inc.
Alumis Inc.'s year-over-year performance is a story of developing a new generation of drugs for the treatment of autoimmune diseases. As a clinical-stage biotech, its 12-month market cap depends entirely on progress in trials of its targeted molecules, which promise greater efficacy and safety than existing treatments.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Alumis, a private biotech company, develops drugs to treat autoimmune diseases. Its growth depends on success in clinical trials. Its valuation dynamics reflect investors' confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alumis is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alumis Inc.
As a biopharmaceutical company, Alumis's performance will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of its clinical trials for autoimmune disease treatments, the success of which will determine its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Alumis is a clinical-stage biotech company developing oral medications for the treatment of autoimmune diseases such as psoriasis. Its goal is to create effective and convenient pills instead of injections. The chart below shows the overall dynamics of the biotech sector, where investors are evaluating the potential of new treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alumis is a biotech company developing drugs to treat autoimmune diseases. Its shares, like many in the sector, are awaiting clinical trial results. Positive data could trigger a rally that defies all market trends, making its performance highly specific.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alumis Inc.
Alumis Inc. is a biotech company specializing in the treatment of immunological diseases. Its weekly stock price, typical for this sector, will be highly volatile and dependent on news about the progress of clinical trials of its drug candidates.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Alumis, like the entire immunology biotech sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect broader scientific breakthroughs or setbacks that impact investor interest in the entire sector. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alumis Inc., a biopharmaceutical company, lives in a world of clinical trial news. This chart clearly shows how insulated its weekly performance is from broader market fluctuations. Does it ignore market noise, following its own trajectory, or does it follow it during lulls?
Market capitalization of the company, segment and market as a whole
ALMS - Market capitalization of the company Alumis Inc.
The data for Alumis Inc. (ALMS) may be inaccurate, as it is likely a private biotech company. If it were publicly traded, its market cap would reflect investors' faith in its scientific platform for developing targeted therapies for autoimmune diseases.
ALMS - Share of the company's market capitalization Alumis Inc. within the market segment - Pharma neurology
Alumis Inc. is a biopharmaceutical company developing drugs for the treatment of autoimmune diseases. Its market share and market capitalization reflect the potential of its developments and investor assessments of its clinical trial prospects.
Market capitalization of the market segment - Pharma neurology
Alumis develops drugs to treat immune diseases. How big is this arena? The chart below shows the overall market capitalization of the neuroscience pharmaceutical sector. Its growth reflects the massive investment and scientific advances in the search for new treatments for complex autoimmune conditions.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Alumis Inc. chart shows how the market is pricing a new generation of drugs for autoimmune diseases. This biotech company's market cap is a bet on the success of its precision-engineered molecules in clinical trials. The chart's dynamics visualize hopes for a breakthrough in the treatment of psoriasis and colitis.
Book value capitalization of the company, segment and market as a whole
ALMS - Book value capitalization of the company Alumis Inc.
The book value of Alumis Inc., a biopharmaceutical company, is based on its material foundation: cutting-edge laboratories, scientific equipment, and significant financial reserves dedicated to the development of immunology drugs. The chart below shows how this physical and financial capital has grown.
ALMS - Share of the company's book capitalization Alumis Inc. within the market segment - Pharma neurology
Alumis Inc. is a biopharmaceutical company whose tangible assets are research laboratories dedicated to developing oral therapeutics for immunological diseases. These R&D centers are its physical base for innovation. The chart shows the percentage of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Pharma neurology
Alumis is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Alumis focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Alumis's core assets are cutting-edge laboratories and R&D centers, where precision drugs for the treatment of immunological diseases are developed. The chart below shows how the company is building its scientific and physical capital to create innovative medicines.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alumis Inc.
Alumis is a biotech company with laboratories. Its post-IPO valuation will reflect pure faith in its platform for developing drugs for immune diseases. The chart will show how these initial expectations will evolve.
Market to book capitalization ratio in a market segment - Pharma neurology
Alumis is a clinical-stage biopharmaceutical company developing drugs for the treatment of autoimmune diseases. Its valuation depends on the success of its developments. The chart shows how its market capitalization, based on potential, exceeds its current tangible assets.
Market to book capitalization ratio for the market as a whole
Alumis is a clinical-stage biopharmaceutical company developing drugs for the treatment of immunological diseases. Its current valuation, relative to the average, is a bet on the success of its research. Investors evaluate the potential of its molecules to become new treatments, which is unrelated to its current tangible assets.
Debts of the company, segment and market as a whole
ALMS - Company debts Alumis Inc.
Alumis Inc., a biopharmaceutical company, is in the clinical stage of developing drugs to treat immunological diseases. This chart reflects its financial strategy. The company is raising significant equity capital to finance expensive and lengthy clinical trials, betting on the future success of its research.
Market segment debts - Pharma neurology
Alumis is a clinical-stage biotech company developing targeted therapeutics for the treatment of immunological diseases. Funding expensive clinical trials is its primary goal. This chart shows how the company's debt policy reflects its capital needs to advance its developments through regulatory hurdles.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alumis Inc.
Alumis Inc. is a biopharmaceutical company focused on treating autoimmune diseases. Drug development in this field requires significant and long-term investment. This chart shows the extent to which the company uses debt financing to conduct clinical trials, which is an indicator of its financial risk and confidence in the success of its candidates.
Market segment debt to market segment book capitalization - Pharma neurology
Alumis is a biotech company developing drugs to treat immunological diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its expensive clinical trials and research to develop new treatments.
Debt to book value of all companies in the market
Alumis Inc. is a biopharmaceutical company focused on treating immunological diseases. Being in clinical development, it requires significant funding. This chart of the overall market appetite for debt risk helps assess the favorable environment for the company to raise funds for its expensive research.
P/E of the company, segment and market as a whole
P/E - Alumis Inc.
Alumis is a biotech company developing oral medications for the treatment of immunological diseases. This chart reflects investor expectations regarding the potential for developing convenient tablet alternatives to injectable medications. Its performance is entirely dependent on clinical trial success and the prospects for entering a multi-billion dollar market.
P/E of the market segment - Pharma neurology
Alumis Inc. is a biotechnology company using a precision approach to developing oral medications for the treatment of immunological diseases. Their goal is to create effective and convenient medications for patients. This chart shows the average valuation for the pharmaceutical sector, reflecting investor expectations for the next generation of drugs for the treatment of autoimmune disorders.
P/E of the market as a whole
Alumis Inc. is a biotech company developing drugs to treat autoimmune diseases. Its valuation, like that of other companies at this stage, is unrelated to the general economic cycles depicted by this chart. Alumis's value is determined solely by the success or failure of its scientific research and clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alumis Inc.
Alumis Inc. is a biopharmaceutical company developing oral therapies for the treatment of immunological diseases. This chart reflects investor expectations for its scientific platform and clinical trials. The valuation is a bet on the company's ability to develop convenient tablet alternatives to existing injectable medications.
%20P%2FE%20Alumis%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alumis-Inc.&v=1772596216660 "Chart of the company's future (projected) P/E Alumis Inc.")
Future (projected) P/E of the market segment - Pharma neurology
Alumis is a biopharmaceutical company developing oral medications for immune-mediated diseases such as psoriasis. This chart reflects the market's confidence in its scientific approach and the potential of its developments. Comparing forecasts with the sector reveals how highly investors view its chances of developing a successful drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772596216675 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Alumis is a clinical-stage biotechnology company focused on developing drugs for the treatment of immunological diseases. Its valuation is based on the future potential of its research and development pipeline. This overall risk appetite chart determines how willing investors are to finance long-term R&D projects with a high degree of uncertainty.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772596216692 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alumis Inc.
Alumis Inc. is a clinical-stage biopharmaceutical company specializing in the development of oral medications for the treatment of immunological diseases. The financial indicators in this chart reflect investments in R&D. Future profits depend on the success of clinical trials and the launch of a new drug.
Profit of companies in the market segment - Pharma neurology
Alumis Inc. is a biopharmaceutical company developing oral medications for the treatment of immunological diseases such as psoriasis. The company aims to create more convenient alternatives to injections. Its sector profitability chart reflects the demand for new treatments for chronic diseases and how investors view the potential of such innovations.
Overall market profit
Alumis Inc. is a biopharmaceutical company developing oral medications for the treatment of immune-mediated diseases. Innovations in this field could offer patients more convenient alternatives to injections. The company's success will depend on the results of clinical trials and reflect progress in creating next-generation drugs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alumis Inc.
Alumis is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of immunological diseases. This chart reflects investor expectations for clinical trial results. Future revenue is entirely dependent on the success of development and subsequent commercialization.
%20profit%20of%20the%20company%20Alumis%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alumis-Inc.&v=1772596216844 "Graph of future (projected) profit of the company Alumis Inc.")
Future (predicted) profit of companies in the market segment - Pharma neurology
Alumis Inc. is a biopharmaceutical company developing oral medications for the treatment of immunological diseases. The forecast on the chart reflects revenue expectations for the entire pharmaceutical industry. It allows one to assess the company's potential for developing patient-friendly treatments for chronic autoimmune disorders.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772596216880 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
The trajectory on this chart shows expectations for a clinical-stage biopharmaceutical company. Alumis's profit forecast hinges on the success of its developments in autoimmune disease treatments. Investor expectations reflected here are based solely on the company's research potential and future clinical trial results.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772596216898 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alumis Inc.
Alumis is a clinical-stage biopharmaceutical company developing drugs to treat immunological diseases. It has no sales revenue. This chart shows how investors assess the scientific potential of its developments. This is a bet on the future success of clinical trials and commercialization.
P/S market segment - Pharma neurology
Alumis is a biopharmaceutical company developing oral therapies for the treatment of immunological diseases. Being in clinical development, its valuation is based on revenue expectations. This chart shows the average valuation in the sector, reflecting how investors view the potential of Alumis's drugs compared to other innovative therapies.
P/S of the market as a whole
Alumis Inc. is a biopharmaceutical company specializing in the development of oral therapeutics for the treatment of immunological diseases. Its valuation is based on the potential of its scientific platform. This chart, showing the average revenue estimate for Alumis, highlights that in biotech, investors often evaluate the likelihood of future scientific breakthroughs rather than current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alumis Inc.
Alumis is a clinical-stage biotechnology company specializing in the development of oral therapies for the treatment of immunological diseases. The company does not yet have commercial products. This chart reflects investor expectations regarding the future success of its developments. It shows the market's assessment of the likelihood of approval and the commercial potential of its drugs.
%20P%2FS%20Alumis%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alumis-Inc.&v=1772596217068 "The graph of the company's future (projected) P/S Alumis Inc.")
Future (projected) P/S of the market segment - Pharma neurology
Alumis Inc. is a biopharmaceutical company developing oral therapies for the treatment of immune-mediated diseases. This chart compares market expectations for its future revenue with other neuroscience pharmaceutical companies. The valuation reflects investor confidence in its scientific platform and the potential of its candidates for the treatment of conditions such as psoriasis.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772596217138 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Alumis is a clinical-stage biopharmaceutical company developing oral medications for the treatment of immune-mediated diseases. Its future depends on the success of clinical trials. Alumis's potential to offer convenient tablet formulations of medications has the potential to transform the market, which is reflected in long-term expectations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772596217193 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alumis Inc.
Alumis Inc. is a clinical-stage biopharmaceutical company focused on the treatment of immunological diseases. The company may not currently have sales revenue. This graph will begin to reflect revenue after the successful commercialization of its products or the conclusion of major partnerships.
Sales of companies in the market segment - Pharma neurology
Alumis Inc. is a biopharmaceutical company specializing in the development of oral medications for the treatment of immune-mediated diseases such as psoriasis. Its goal is to create convenient and effective alternatives to injections. This chart shows overall sales in the pharmaceutical sector, illustrating the significant market potential for innovative treatments for chronic diseases.
Overall market sales
Alumis is a biopharmaceutical company developing oral therapies for the treatment of immunological diseases. This overall economic activity chart is important for Alumis through the lens of funding. A stable economy and active stock market facilitate raising capital for costly clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alumis Inc.
Alumis is a biotech company developing oral therapies for the treatment of immunological diseases such as psoriasis. Currently in the clinical stage, its future revenue depends on the success of trials and regulatory approval. This chart reflects analyst expectations regarding the potential of its research in the competitive field of immunology.
%20sales%20of%20the%20company%20Alumis%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alumis-Inc.&v=1772596217469 "Schedule of future (projected) sales of the company Alumis Inc.")
Future (projected) sales of companies in the market segment - Pharma neurology
Alumis Inc. is a biopharmaceutical company developing oral therapies for immune-mediated diseases. This chart shows projected revenues for the entire pharmaceutical sector. While it provides a general overview, Alumis's success depends on the clinical results of its innovative drugs and their potential in the immunology market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772596217527 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Alumis is a clinical-stage biopharmaceutical company developing drugs for the treatment of immunological diseases. Its prospects depend on the success of clinical trials. This graph, reflecting the overall economic situation, influences the investment climate. During periods of economic stability and growth, investors are more willing to finance long-term and risky projects in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772596217551 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alumis Inc.
Alumis is a biopharmaceutical company developing drugs to treat immunological diseases. For a company in clinical development, this chart reflects its capital burn rate. It shows how Alumis manages its research expenses, striving to develop a marketable drug that will recoup all investments.
Market segment marginality - Pharma neurology
Alumis is a clinical-stage biopharmaceutical company specializing in the development of oral therapeutics for the treatment of immunological diseases. This chart reflects its operational structure, highlighting its high R&D expenditures. It allows for comparison with other biotech companies seeking to develop new, convenient treatments.
Market marginality as a whole
Alumis Inc. is a clinical-stage biopharmaceutical company specializing in the development of oral therapeutics for the treatment of immune-mediated diseases. Its future profitability depends on the success of its clinical programs. This total market profitability chart serves as a contrast to biotechnology, where scientific breakthroughs in the development of convenient treatments can lead to massive commercial success.
Employees in the company, segment and market as a whole
Number of employees in the company Alumis Inc.
Alumis is a clinical-stage biopharmaceutical company specializing in the development of oral therapeutics for the treatment of immunological diseases. This chart shows the growing team of scientists and clinicians. The increase in staff directly reflects progress in clinical programs and the expansion of the research platform.
Share of the company's employees Alumis Inc. within the market segment - Pharma neurology
This indicator reflects the scientific focus of Alumis Inc. The company's pharmaceutical sector is focused on developing oral medications for the treatment of immunological diseases such as psoriasis. This team of scientists strives to create patient-friendly tablet formulations of medications that can compete with injectables.
Number of employees in the market segment - Pharma neurology
Alumis Inc. is a biopharmaceutical company developing oral medications for the treatment of immunological diseases. Creating pills instead of injections could dramatically improve patients' quality of life. This graph illustrates how innovations in drug delivery methods require new approaches in chemistry and pharmacology, engaging the relevant specialists.
Number of employees in the market as a whole
Alumis Inc. is a biotechnology company focused on precision immunology. Its value is determined by the success of its scientific platform in developing new drugs. This overall workload schedule is irrelevant to its prospects, which are entirely focused on research and clinical development.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alumis Inc. (ALMS)
Alumis is a clinical-stage biotech developing drugs for the treatment of immunological diseases. This chart demonstrates the company's high scientific potential. The astronomical market capitalization per research employee reflects investor expectations for its innovative platform, not its current financial performance.
%20of%20the%20company%20Alumis%20Inc.%20(ALMS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alumis-Inc.-ALMS&v=1772596217876 "Chart of market capitalization per employee (in thousands of dollars) of the company Alumis Inc. (ALMS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Alumis develops oral drugs for the treatment of immunological diseases. As with any biotech, its value is determined by its pipeline. This chart shows the market's perception of the team's research. A high value reflects the potential for future blockbusters.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772596217893 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Alumis Inc. is a biotech company specializing in immunology. This chart reflects its estimated scientific potential. Like other R&D companies, the high cost per employee is not a reflection of current revenue, but rather a bet by investors that its research will lead to successful treatments for autoimmune diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772596217907 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alumis Inc. (ALMS)
Alumis Inc. is a clinical-stage biotechnology company developing oral medications (tablets) for the treatment of autoimmune diseases (e.g., psoriasis). The company has no commercial profit. This chart shows the net loss (R&D costs) per scientist working on the development of a new drug.
%20Chart%20Alumis%20Inc.%20(ALMS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alumis-Inc.-ALMS&v=1772596217938 "Company Profit Per Employee (in thousands of dollars) Chart Alumis Inc. (ALMS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Alumis Inc. is a clinical-stage biotech developing drugs for the treatment of autoimmune diseases. It uses a platform to discover precise small molecules. This chart shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company invests in its scientists to advance drug candidates compared to other immunology biotechs.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772596218001 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Alumis (ALMS) is a clinical-stage biotech developing oral medications for the treatment of immunological diseases (e.g., psoriasis). Like other biotechs in the R&D phase, this graph shows the loss per employee. It reflects the high costs of research and development incurred by the company's scientists and physicians in the hopes of developing a new treatment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772596218042 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alumis Inc. (ALMS)
Alumis is a biotechnology company developing drugs to treat immunological diseases. This chart reflects the company's activity in the clinical trials stage. Revenue per employee is currently absent, as the company is focused on research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alumis-Inc.-ALMS&v=1772596218051 "Sales chart per company employee Alumis Inc. (ALMS)")
Sales per employee in the market segment - Pharma neurology
Alumis is a clinical-stage biotech company specializing in immunology treatments. This chart shows the average revenue per employee in this segment. It serves as a benchmark for comparison with a sector where R&D productivity is measured not by revenue but by progress in the research that is expected to generate it.
Sales per employee for the market as a whole
Alumis is a clinical-stage biopharmaceutical company focused on immunology and neuroscience. They have no commercial products. This figure would be zero. Their entire staff (scientists) is focused on research and development of new drugs, and funding comes from investors, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company Alumis Inc. (ALMS)
Alumis is an early-stage biotech company specializing in immunology and neuroscience. The bearish sentiment seen in this chart is a standard bet against R&D biotech companies. Bears point to a lack of revenue, high cash burn, and a low probability of success in clinical trials, which will take years.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alumis-Inc.-ALMS&v=1772596218285 "Short Shares Chart for the Company Alumis Inc. (ALMS)")
Shares shorted by market segment - Pharma neurology
Alumis is a clinical-stage biotech developing oral medications (tablets) for the treatment of immunological diseases such as psoriasis. This chart illustrates the overall sentiment in the sector. It reflects investor skepticism toward biotechs that don't yet have revenue and concerns about the intense competition in the immunology market.
Shares shorted by the overall market
Alumis (ALMS) is a clinical-stage biotech company. Its survival is entirely dependent on access to capital markets to fund R&D. This indicator of market pessimism is an existential threat. Rising fears mean the window for raising capital is closing, jeopardizing its entire scientific program.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alumis Inc. (ALMS)
Alumis (ALMS) is a biotech company developing oral (tablet) drugs for the treatment of autoimmune diseases such as psoriasis and neurological disorders. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) during periods of anticipation and high R&D uncertainty.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alumis-Inc.-ALMS&v=1772596218437 "RSI 14 indicator chart for the company's stock Alumis Inc. (ALMS)")
RSI 14 Market Segment - Pharma neurology
Alumis (ALMS) is a biotech company developing precision drugs for the treatment of autoimmune diseases. This chart measures the pulse of the Pharma/Neurology/Immunology sector. It helps distinguish Alumis' clinical trial success from overall overheating or overselling across the biotech sector.
RSI 14 for the overall market
Alumis (ALMS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALMS (Alumis Inc.)
Alumis (ALMS) is a clinical-stage biopharmaceutical company specializing in precision medicine for the treatment of autoimmune diseases. It uses a platform to discover targeted drugs. This chart shows the average Wall Street forecast. It reflects analysts' assessments of the potential of their lead candidate for the treatment of psoriasis.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALMS-Alumis-Inc.&v=1772596218737 "A chart showing analyst consensus forecasts for the expected stock price. ALMS (Alumis Inc.)")
The difference between the consensus estimate and the actual stock price ALMS (Alumis Inc.)
Alumis (ALMS) is a biotech developing targeted therapies (TYK2 inhibitors) for the treatment of autoimmune diseases such as psoriasis and lupus. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the significant potential analysts see in their oral drug pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALMS-Alumis-Inc.&v=1772596218817 "A chart showing the difference between the consensus forecast and the actual stock price. ALMS (Alumis Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Alumis is a biotech company developing precision drugs for the treatment of autoimmune and neuroinflammatory diseases. This chart shows analysts' overall expectations across the neuroscience sector. It reflects experts' confidence in the success of new targeted approaches to treating complex immune disorders.
Analysts' consensus forecast for the overall market share price
Alumis Inc. is a biotech company developing oral (tablet-based) therapies for the treatment of autoimmune diseases such as psoriasis. This chart shows the overall risk appetite. For Alumis, as a clinical-stage company, overall market optimism is important for raising the capital needed to compete in this highly competitive field.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alumis Inc.
Alumis (ALMS) is a clinical-stage biotech focused on precision immunology—developing oral (tablet) therapies for autoimmune diseases (psoriasis, lupus). This graph represents pure R&D investment. Its valuation reflects the market's faith in their scientific platform and the potential of their lead drug in this competitive field.
AKIMA Market Segment Index - Pharma neurology
Alumis (ALMS) is a clinical-stage biotech focused on precision immunology; the company develops innovative oral (tablet) therapies for the treatment of autoimmune diseases (psoriasis). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D rate (ALMS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Alumis is a biotech company developing oral medications for the treatment of immune-mediated diseases (psoriasis, lupus). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this recent IPO story with an advanced pipeline compares to overall economic trends and interest in the sector.
